PMID- 29311965
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1664-042X (Print)
IS  - 1664-042X (Electronic)
IS  - 1664-042X (Linking)
VI  - 8
DP  - 2017
TI  - The Associations between Apolipoprotein E Gene Epsilon2/Epsilon3/Epsilon4 
      Polymorphisms and the Risk of Coronary Artery Disease in Patients with Type 2 
      Diabetes Mellitus.
PG  - 1031
LID - 10.3389/fphys.2017.01031 [doi]
LID - 1031
AB  - Background and Objective: Apolipoprotein E (APOE) plays important roles in 
      lipoprotein metabolism and cardiovascular disease. Evidence suggests the APOE 
      gene epsilon2/epsilon3/epsilon4 (epsilon2/epsilon3/epsilon4) polymorphisms might be associated with 
      the susceptibility of coronary artery disease (CAD) in patients with type 2 
      diabetes mellitus (T2DM). However, no clear consensus has yet been established. 
      Therefore, the aim of this meta-analysis is to provide a precise conclusion on 
      the potential association between APOE epsilon2/epsilon3/epsilon4 polymorphisms and the risk of CAD 
      in patients with T2DM based on case-control studies. Methods: Pubmed, Embase, 
      Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases were 
      searched for all relevant studies prior to August 2017 in English and Chinese 
      language. The pooled odds ratios (ORs) and their corresponding 95% confidence 
      intervals (CIs) were used to assess the strength of the relationships. The 
      between-study heterogeneity was evaluated by Cochran's Q-test and the I(2) index 
      to adopt fixed- or random- effect models. Results: A total of 13 studies were 
      eligible for inclusion. There was evidence for significant associations between 
      APOE epsilon4 mutation and the risk of CAD in patients with T2DM (for epsilon3/epsilon4 vs. epsilon3/epsilon3: 
      OR = 1.69, 95% CI = 1.38-2.08, P < 0.001; for epsilon4/epsilon4 vs. epsilon3/epsilon3: OR = 2.72, 95% CI 
      = 1.61-4.60, P < 0.001; for epsilon4/epsilon4+epsilon3/epsilon4 vs. epsilon3/epsilon3: OR = 1.83, 95% CI = 1.52-2.22, 
      P < 0.001; for epsilon4 allele vs. epsilon3 allele: OR = 1.64, 95% CI = 1.40-1.94, P < 
      0.001). In contrast, no significant associations were found in genetic model of 
      APOE epsilon2 mutation (for epsilon2/epsilon2 vs. epsilon3/epsilon3: OR = 1.67, 95% CI = 0.90-3.09, P = 0.104; 
      for epsilon2/epsilon3 vs. epsilon3/epsilon3: OR = 1.18, 95% CI = 0.93-1.51, P = 0.175; for epsilon2/epsilon2+epsilon2/epsilon3 
      vs. epsilon3/epsilon3: OR = 1.26, 95% CI = 0.88-1.82, P = 0.212; for epsilon2 allele vs. epsilon3 allele: 
      OR = 1.34, 95% CI = 0.98-1.84, P = 0.07). Conclusions: The APOE gene epsilon4 mutation 
      is associated with an increased risk of CAD in patients with T2DM, while the epsilon2 
      variation has null association with this disease.
FAU - Luo, Jian-Quan
AU  - Luo JQ
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Ren, Huan
AU  - Ren H
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, 
      Central South University, Changsha, China.
FAU - Banh, Hoan Linh
AU  - Banh HL
AD  - Department of Family Medicine, Faculty of Medicine and Dentistry, University of 
      Alberta, Edmonton, AB, Canada.
FAU - Liu, Mou-Ze
AU  - Liu MZ
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Xu, Ping
AU  - Xu P
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Fang, Ping-Fei
AU  - Fang PF
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Xiang, Da-Xiong
AU  - Xiang DX
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
LA  - eng
PT  - Journal Article
DEP - 20171212
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC5732920
OTO - NOTNLM
OT  - apolipoprotein E
OT  - coronary artery disease
OT  - epsilon2
OT  - epsilon3
OT  - epsilon4
OT  - genetic polymorphism
OT  - type 2 diabetes mellitus
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:01
PMCR- 2017/12/12
CRDT- 2018/01/10 06:00
PHST- 2017/08/22 00:00 [received]
PHST- 2017/11/28 00:00 [accepted]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:01 [medline]
PHST- 2017/12/12 00:00 [pmc-release]
AID - 10.3389/fphys.2017.01031 [doi]
PST - epublish
SO  - Front Physiol. 2017 Dec 12;8:1031. doi: 10.3389/fphys.2017.01031. eCollection 
      2017.